Stifel raised the firm's price target on Enliven to $80 from $60 and keeps a Buy rating on the shares. The firm is "more bullish" on its second-line and later thesis for ELVN-001 following EHA26 updates and the firm's checks with key opinion leader physicians, the analyst tells investors. The firm is increasing its view of the odds of success of the ELVN-001 in second-line and later chronic myeloid leukemia program to 85% from 65%.
